Clinical Performance Partners Launches New Web Site
Clinical Performance Partners, Inc. (CPP) announces the launch of their website (www.clinicalperformancepartners.com).
Contact: Beth Harper FOR IMMEDIATE RELEASE
Phone: 817-946-4892
Email: bharper@clinicalperformancepartners.com
CLINICAL PERFORMANCE PARTNERS LAUNCHES NEW WEBSITE
KELLER, TX June 19, 2008 – Clinical Performance Partners, Inc. (CPP) announces the launch of their website (www.clinicalperformancepartners.com).
“In addition to establishing a web presence for the company, the goal of the website is to serve as a valuable resource to the industry for all things related to patient recruitment / retention and site relationship management” says Beth Harper, President of Clinical Performance Partners, Inc.
The website features a listing of patient recruitment service providers with links to their websites. In addition, viewers can search for articles related to patient recruitment and site relationship management, as well as download sample tools and templates developed by CPP, Inc.
“As a long-time champion and advocate for educating the industry on the process and practice of patient recruitment, I am delighted to share my interest, experience and resources as we all strive to overcome the chronic challenges associated with patient recruitment” says Harper.
“Predicting, managing, supporting and enhancing site performance in clinical trials is not only our mission by my personal passion” notes Harper who celebrates some 25 years of “in the trenches” healthcare and clinical research experience this year.
About Clinical Performance Partners - CPP is a consulting firm dedicated to designing and implementing innovative and practical solutions for improving site performance and accelerating clinical trials results for the Life Sciences Industry. www.clinicalperformancepartners.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
